DAX8.305-0,6%  Dow15.3030,1%  Euro1,29400,0% 
ESt502.764-0,5%  Nas3.4590,0%  Öl102,60,0% 
TDax958,0-0,3%  Nikkei14.6130,9%  Gold1.387-0,3% 
Home > Aktien > Bioalliance PharmaAct Nom Cat-P- Aktie > Nachrichten zu Bioalliance PharmaAct Nom Cat-P-

Bioalliance PharmaAct Nom Cat-P- Aktie [WKN: A0HMXA / ISIN: FR0010095596]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)NewsBilanz/GuVDividende/HVZertifikateDepot
Times + SalesChart-AnalyseAnalysenSchätzungenTermineOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele ProfilKnock-OutsmyHome
OrderbuchRealtime Stuttgart  InsidertradesFondsSenden
HistorischRealtime PushmyNews  im ForumAnleihen 

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur Bioalliance PharmaAct Nom. Cat-P-. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur Bioalliance PharmaAct Nom. Cat-P-

14.05.13BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at April 30, 2013
13.05.13BioAlliance Pharma announces DSMB second positive recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer
19.04.13BioAlliance Pharma SA : Publication of the 2012 Registration Document
15.04.13BioAlliance Pharma Updates on Major Achievements of 2012 and Publishes Its 2012 Consolidated Financial Statements and Income for Q1 2013
15.04.13BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US For the Treatment of Herpes Labialis
08.04.13BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2013
12.03.13BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei
04.03.13BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at February 28, 2013
28.02.13BioAlliance Pharma Signs a Collaborative Agreement with One of the Worldwide Leaders in Vaccines for a Vaccine Application of Its Patented Lauriad® Mucoadhesive Technology
14.02.13BioAlliance Pharma announces the forthcoming extension of its phase II clinical trial with Validive® in the United States
07.02.13BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at January 31, 2013
25.01.13Set up of a standby equity financing (PACEO®) to support the growth projects of BioAlliance Pharma
09.01.13BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2012
07.01.13BioAlliance Pharma Announces the Launch of Oravig® in the United States by Its New Partner, Vestiq Pharmaceuticals
03.01.13BioAlliance Pharma receives a guarantee from Coface to finance its export activities
20.12.12BioAlliance Pharma Announces the Registration of Sitavig® in European Countries
19.12.12BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation without Modification of the Phase III Clinical Trial with Livatag® in Primary Liver Cancer
06.12.12BioAlliance Pharma: First meeting of the DSMB of the ReLive trial and continuation without modification of the Phase III clinical trial with Livatag® in primary liver cancer
06.12.12BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2012
14.11.12BioAlliance Pharma SA: Quarterly information as of September 30, 2012
07.11.12BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2012
18.10.12BioAlliance Pharma: New agreement signed for the distribution of Loramyc® in Iran with Shafayab Gostar
05.10.12BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at September 30, 2012
01.10.12BioAlliance Pharma SA: Presentation of Phase I clinical results with AMEP® biotherapy in the treatment of metastatic melanoma
24.09.12BioAlliance Pharma announces the execution of its licensing agreement with Vestiq Pharmaceuticals for Oravig® in the US
13.09.12BioAlliance Pharma : Key milestones and consolidated accounts for the first semester of 2012
06.09.12BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at August 31, 2012
06.08.12BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at July 31, 2012
26.07.12BioAlliance Pharma announces the grant of US patent covering Sitavig®
19.07.12BioAlliance Pharma announces a license agreement on Oravig® In the United States with Vestiq Pharmaceuticals
12.07.12BioAlliance Pharma extends and strengthens the protection of AMEP® with the grant of two patents in the US
04.07.12BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at June 30, 2012
02.07.12BioAlliance Pharma: Progress in the development of Loramyc® in Japan towards its registration by the partner Sosei
18.06.12BioAlliance Pharma Reinforces Its Development Team with the Appointment of Louis Kayitalire, MD, as Head of Research and Development
13.06.12BioAlliance Pharma and Teva Announce First License Agreement for Sitavig® for Israel
04.06.12BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at May 31, 2012
31.05.12BioAlliance Pharma: Combined Shareholders Meeting
29.05.12BioAlliance Pharma SA : Receivability of Sitavig® US Registration Dossier (NDA) for the Treatment of Recurrent Orofacial Herpes Validated by the FDA
14.05.12BioAlliance Pharma SA: Initiation of ReLive, phase III clinical trial with Livatag® In primary liver cancer
10.05.12BioAlliance Pharma: Disclosure of total number of voting rights and number of shares in the capital at April 30, 2012

Anzeige

ANZEIGE

Seite: 1234567
Wie bewerten Sie diese Seite?
schlecht sehr gut
Problem mit dieser Seite?
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2013 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Knock-Outs Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon Börse App iPhone Börse App Android Börse App iPad